A combination of two drugs destroys precancerous polyps in the colon without effects on normal tissues, thus opening a new avenue for chemoprevention of colon cancer, a team of scientists from the University of Texas MD Anderson Cancer Center Report in editing advanced online edition of Nature. The scheme, so far tested in mouse models and tissues of human colon cancer in the laboratory, appears to be a problem with chemopreventive agents – must be taken long term remains effective, expose patients to potential side effects, said Xiangwei lead author Wu, Ph.D., associate professor in MD Anderson Department of Head and Neck Surgery.
“This combination can be short term and periodically to provide long term, which would be a new approach to chemotherapy,” said Wu
The team found that combining vitamin A acetate (RAC) and Camino, the absence of tumor necrosis factor apoptosis inducing ligand to kill pre-cancerous polyps and inhibits tumor growth in mice that are deficient in a tumor suppressor gene. This gene, adenomatous polyposis coli (APC) and its downstream signaling molecules, are mutated or deficient in 80 percent of all cancers of the colon of man, “said Wu.
A new study supports the role of ‘old antidepressant drugs work in patients with bipolar depression and melancholy that are resistant to treatment or had side effects of antidepressant drugs, past or present.
These antidepressants, methylphenidate and dexamphetamine have been largely neglected in recent decades because of concerns about the effectiveness, tolerance and dependence.
But in this study, researchers led by Professor Gordon Parker and Dr. Heather Brotchie Black Dog Institute, had distinctive clinical benefits of a significant percentage of these psychostimulant drugs – evaluated in a sample of 50 patients (60 percent of women with a mean age of 49 years).
The study was published in the latest issue of world-renowned psychiatry, Acta Primary Care.
“Two thirds of these patients with treatment-resistant depression received a psychostimulant prescribed as monotherapy or as an enhancement of the drug – so that side effects are rare and generally mild,” said the professor.
The identification of compounds may be promising candidates for drug development research has become easier to follow by the Walter and Eliza Hall Institute of Medical Chemistry group.Dr Jonathan Bael and Dr. Georgina Holloway developed a series of filters that can be used to remove these molecules can come in many false positives when testing a library of chemical compounds that may be useful in drug development.
high-performance chemical detection (CTH) seeks to identify chemical compounds that interact with a target protein and therefore potential candidates for drug development. There may be 30,000 to one million compounds in a library and screening thousands of compounds can be identified as “positive” interaction with a protein of interest. These compounds become the subject of time medicinal chemistry that scientists are trying to perfect for the entry into the drug development pipeline.
Dr. Bael, said 10 percent of the compounds at any screening library available in the market may appear as false positives, which could lose hundreds of hours of the scientists who do the work of medicinal chemistry to optimize these molecules.